drugset / Trial / NCT05685472
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label study evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor activity of MEDI5752 in Japanese patients with advanced solid solid tumors.
Timeline
- Start
- 2022-12-08
- Primary completion
- 2023-08-08
- Completion
- 2025-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volrustomig | Monoclonal antibody | — | — |